Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: winners18	6/17/2016 11:20:45 PM
	of 63325

new adc using same toxin class as immunomedics 09:30 Preclinical Profiles of Topoisomerase I Inhibitor Exatecan Derivative-Based HER2-Targeting ADC Takeshi HondaSenior Director, Daiichi Sankyo SynopsisADC covalently connected with exatecan derivatives via a cleavable linker system showed low aggregation ratio, high drug-to-antibody ratio (DAR), & strong efficacyDS-8201a is a novel anti-HER2 ADC with one of the exatecan derivatives & Phase I dose escalation part is ongoingDS-8201a was not only effective in a T-DM1-insensitive PDX model with high HER2 expression but also anti-tumor efficacy against several breast cancer PDX models with low HER2 expressio

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next